• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4674215)   Today's Articles (33)
Download
Number Citation Analysis
1
Luus L, Hurov K, Lahdenranta J, Shah C, Devlen A, Kristensson J, Brown P, Bray C, Cohen H, Campbell C, Mudd G, Upadhyaya P, McDonnell K, Xu H, Jeffrey P, Brandish PE, Keen N. Abstract 1832: EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a Bicycle tumor-targeted immune cell agonist®. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-1832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
2
Rigby M, Bennett G, Chen L, Mudd GE, Harrison H, Beswick PJ, Van Rietschoten K, Watcham SM, Scott HS, Brown AN, Park PU, Campbell C, Haines E, Lahdenranta J, Skynner MJ, Jeffrey P, Keen N, Lee K. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Mol Cancer Ther 2022;21:1747-1756. [PMID: 36112771 PMCID: PMC9940631 DOI: 10.1158/1535-7163.mct-21-0875] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Revised: 07/01/2022] [Accepted: 09/09/2022] [Indexed: 01/12/2023]
3
Cohen H, Bray C, Kanakia D, Lahdenranta J, Upadhyaya P, Hurov K, Kristensson J, Jobaliya C, Bannish G, Cotty A, McDonnell K, Hirschberg S, Hazard S, Smethurst D, Keen N, Blakemore SJ. Abstract A65: Development of a CD137 receptor occupancy assay to support the Phase I/II study of BT7480, a Bicycle® tumor-targeted immune cell agonist ® (Bicycle TICA™). Cancer Immunol Res 2022. [DOI: 10.1158/2326-6074.tumimm22-a65] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
4
Upadhyaya P, Kristensson J, Lahdenranta J, Repash E, Ma J, Kublin J, Mudd GE, Luus L, Jeffrey P, Hurov K, McDonnell K, Keen N. Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology. J Med Chem 2022;65:9858-9872. [PMID: 35819182 PMCID: PMC9340768 DOI: 10.1021/acs.jmedchem.2c00505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
5
Dufort FJ, Leitheiser CJ, Mudd G, Kristensson J, Rezvaya A, Gaynor K, Uhlenbroich S, Urbonas L, Scott H, Chen L, Harrison H, Skynner M, McDonnell K, Brandish PE, Keen N. Abstract 4233: Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule designed to induce targeted tumor cytotoxicity. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-4233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
6
Cohen H, Kanakia D, Lahdenranta J, Upadhyaya P, Hurov K, Kristensson J, Jobaliya C, Bannish G, Cotty A, McDonnell K, Hirschberg S, Brandish P, Hazard S, Smethurst D, Keen N, Blakemore SJ. Abstract 1976: Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA®). Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-1976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
7
Hurov K, Lahdenranta J, Upadhyaya P, Haines E, Cohen H, Repash E, Kanakia D, Ma J, Kristensson J, You F, Campbell C, Witty D, Kelly M, Blakemore S, Jeffrey P, McDonnell K, Brandish P, Keen N. BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism. J Immunother Cancer 2021;9:jitc-2021-002883. [PMID: 34725211 PMCID: PMC8562524 DOI: 10.1136/jitc-2021-002883] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/01/2021] [Indexed: 12/30/2022]  Open
8
Dufort F, Leitheiser C, Mudd G, Kristensson J, Rezvaya A, Repash E, Haines E, Gaynor K, Uhlenbroich S, Urbonas L, Allen H, Harrison H, Chen L, Brandish P, McDonnell K, Keen N. 789 Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule to enhance targeted tumor cytotoxicity. J Immunother Cancer 2021. [DOI: 10.1136/jitc-2021-sitc2021.789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]  Open
9
Cohen H, Campbell C, Hurov K, Lahdenranta J, Gelb T, Galbraith D, Rozelle D, Nagy M, Au Q, Parnell E, Brandish P, Hazard S, Smethurst D, Keen N, Blakemore S. 2 Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™). J Immunother Cancer 2021. [DOI: 10.1136/jitc-2021-sitc2021.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]  Open
10
Upadhyaya P, Mudd G, Hurov K, Lahdenranta J, Repash E, Kristensson J, McDonnell K, Brandish P, Jeffrey P, Keen N. 888 An integrative approach to optimize a synthetic EphA2/CD137 agonist: balancing potency, physiochemical properties, and pharmacokinetics to achieve robust anti-tumor activity. J Immunother Cancer 2021. [DOI: 10.1136/jitc-2021-sitc2021.888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]  Open
11
Hurov K, Lahdenranta J, Upadhyaya P, Kanakia D, Repash E, You F, Ma J, Haines E, Cohen H, McDonnell K, Brandish PE, Jeffrey P, Keen N. Abstract 1728: Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle®tumor-targeted immune cell agonist (TICA™). Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
12
Lahdenranta J, Bennett G, Huxley P, Mudd G, Upadhyaya P, Jeffrey P, Keen N. Abstract 1319: Rapid accumulation of cytotoxic payload in tumor tissue drives BT5528 activity in tumor models. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
13
Lahdenranta J, Blakemore SJ, Hurov K, Grenley MO, Upadhyaya P, Campbell C, Repash E, Haines E, Brandish PE, Klinghoffer RA, Keen N. Abstract 1724: Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA™) activates the local tumor microenvironment. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
14
Kanakia DN, Upadhyaya P, Lahdenranta J, Repash E, Haines E, McDonnell K, Hurov K, Brandish P, Keen N. Abstract PO076: Development of a CD137 (4-1BB) receptor occupancy assay using fluorescently labelled Bicycles®. Cancer Immunol Res 2021. [DOI: 10.1158/2326-6074.tumimm20-po076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
15
Repash EM, Upadhyaya P, Lahdenranta J, Kublin J, Ma J, Kleyman M, Chen L, Haines E, Battula S, McDonnell K, Hurov K, Brandish P, Keen N. Abstract PO077: BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized 4-1BB agonism. Cancer Immunol Res 2021. [DOI: 10.1158/2326-6074.tumimm20-po077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
16
Upadhyaya P, Lahdenranta J, Hurov K, Battula S, Dods R, Haines E, Kleyman M, Kristensson J, Kublin J, Lani R, Ma J, Mudd G, Repash E, Van Rietschoten K, Stephen T, You F, Harrison H, Chen L, McDonnell K, Brandish P, Keen N. Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist. J Immunother Cancer 2021;9:jitc-2020-001762. [PMID: 33500260 PMCID: PMC7839861 DOI: 10.1136/jitc-2020-001762] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/15/2020] [Indexed: 12/13/2022]  Open
17
Battula S, Mudd G, Upadhyaya P, Kristensson J, Kleyman M, Repash E, Kublin J, Ma J, Haines E, Hurov K, Chen L, Lahdenranta J, Beswick P, McDonnell K, Keen N. Abstract 6703: A fully synthetic EphA2/4-1BB tumor-targeted immune cell agonist (TICATM) induces tumor localized 4-1BB agonism. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-6703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
18
Hurov K, Upadhyaya P, Lahdenranta J, Kublin J, Ma J, Repash E, Kleyman M, Kristensson J, Chen L, Haines E, Battula S, McDonnell K, Keen N. Abstract 5552: BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICATM) induces tumor localized 4-1BB agonism. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5552] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
19
Bennett G, Brown A, Mudd G, Huxley P, Van Rietschoten K, Pavan S, Chen L, Watcham S, Lahdenranta J, Keen N. MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther 2020;19:1385-1394. [PMID: 32398269 DOI: 10.1158/1535-7163.mct-19-1092] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2019] [Revised: 02/24/2020] [Accepted: 04/29/2020] [Indexed: 11/16/2022]
20
Rigby M, Beswick P, Mudd G, Rietschoten KV, Chen L, Watcham SM, Allen H, Brown A, Harrison H, Bennett G, Jeffrey P, Park PU, Koehler M, Keen N. Abstract 4479: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4479] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
21
Hurov KE, Upadhyaya P, Kublin J, Zhou X, Kristensson J, Lani R, Mudd G, Rietschoten KV, An F, Lahdenranta J, Chen L, Bennett G, McDonnell K, Park P, Keen N. Abstract 3257: Activation of CD137 using multivalent and tumor targeted Bicyclic peptides. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
22
Stuart DD, Shao W, Mishina Y, Feng Y, Caponigro G, Cooke VG, Rivera S, Shen F, Korn J, Griner LAM, Nishiguchi G, Taft B, Wan L, Subramanian S, Lou Y, Setti L, Burger M, Tamez V, Rico A, Aversa R, Tellew J, Haling JR, Polyakov V, Lambert A, Zang R, Abbema AV, Hekmat-Nejad M, Amiri P, Singh M, Keen N, Dillon MP, Lees E, Sellers WR, Ramurthy S. Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-ddt01-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
23
Bennett G, Huxley P, Brown A, Mudd G, Rietschoten KV, Pavan S, Chen L, Watcham SM, Park PU, Keen N. Abstract 5855: Bicycle Drug Conjugates targeting EphA2 for the treatment of solid tumors: Discovery and selection of BT5528. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
24
Park PU, Lani R, Mudd G, Kristensson J, Rietschoten KV, An WF, Bennett G, McDonnell K, Keen N. Abstract 3756: Small synthetic, multivalent bicyclic peptides that activate T cell costimulatory protein CD137. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-3756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
25
Shao W, Mishina YM, Feng Y, Caponigro G, Cooke VG, Rivera S, Wang Y, Shen F, Korn JM, Mathews Griner LA, Nishiguchi G, Rico A, Tellew J, Haling JR, Aversa R, Polyakov V, Zang R, Hekmat-Nejad M, Amiri P, Singh M, Keen N, Dillon MP, Lees E, Ramurthy S, Sellers WR, Stuart DD. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF. Cancer Res 2018;78:1537-1548. [PMID: 29343524 DOI: 10.1158/0008-5472.can-17-2033] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Revised: 11/22/2017] [Accepted: 01/11/2018] [Indexed: 11/16/2022]
PrevPage 1 of 3 123Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Open (13)